Skip to main content
Livermore
Livermore
ZHEN

Annovis Bio, Inc.

ANVS
Exchange
NYSE
Industry
Pharmaceutical Preparations
SEC CIK
0001477845

No open-market purchases or sales by Annovis Bio, Inc. insiders were filed in the last 90 days; 61 institutions reported holding it in 13F filings for Q2 2026, worth $20.2M in total; no superinvestor holds it.

Holders of 5% or more of ANVS

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Annovis Bio, Inc., largest stake first. The change is against the holder's previous filing.

Holders of 5% or more of ANVS
HolderLatest formStakeChangeFirst filedLatest filingFiling
Highbridge Capital Management LLC13G6.10%2.78M sharesNewAug 14, 20261 filingAug 14, 2026SEC
Empery Asset Management, LP13G5.64%2.40M sharesNewJul 29, 20261 filingJul 29, 2026SEC

Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.

13D and 13G filings

7 Schedule 13D and 13G filings on Annovis Bio, Inc., newest first, including old-format filings without a stake.

Schedule 13D and 13G filings on ANVS
Filed (ET)FilerFormStakeChangeEvent dateFiling
Aug 14, 202612:39 PM ETHighbridge Capital Management LLC13G6.10%2.78M sharesNewJun 30, 2026SEC
Jul 29, 20264:17 PM ETEmpery Asset Management, LPand 1 other13G5.64%2.40M sharesNewJun 30, 2026SEC
May 12, 202512:06 PM ETCVI Investments, Inc.and 1 other13G/A4.90%1.00M shares−0.20 ppfrom 5.10%Below 5%Mar 31, 2025SEC
Feb 10, 202511:07 AM ETCVI Investments, Inc.and 1 other13G5.10%1.00M sharesNewFeb 3, 2025SEC
Nov 28, 2023Hirschman Orin13G/AOld format–––SEC
Nov 8, 2023Hirschman Orin13GOld format–––SEC
Jan 28, 2021Hirschman Orin13G/AOld format–––SEC

Form 144: proposed insider sales

Notices from officers, directors and other affiliates planning to sell Annovis Bio, Inc. shares.

No Form 144 notices for Annovis Bio, Inc. are on file.